Evidence map›Paper›PMID 34083207›Full record

ArticleAnnals of the rheumatic diseases2021

B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus.

Scott A Jenks, Chungwen Wei, Regina Bugrovsky, Aisha Hill, Xiaoqian Wang, Francesca M Rossi, Kevin Cashman, Matthew C Woodruff, Laura D Aspey, S Sam Lim and 3 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Annals of the rheumatic diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Extrafollicular CD19Journal of translational autoimmunity · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Scott A Jenks *Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID 0000-0001-7485-8331
Chungwen Wei *Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Regina BugrovskyDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Aisha HillDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Xiaoqian WangDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Francesca M RossiDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Kevin CashmanDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Matthew C WoodruffDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Laura D AspeyDepartment of Dermatology, Emory University School of Medicine, Atlanta, Georgia, USA.
S Sam LimDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Gaobin BaoDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Cristina DrenkardDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.
Ignacio SanzDepartment of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA ignacio.sanz@emory.edu.
Emory University · US

Funding

Regulation of B cell Responses in SLE and Other Autoimmune DiseasesU19AI110483 · NIAID · EMORY UNIVERSITY · PI Ignacio E. Sanz · 2014 to 2026
$76.6M
The Georgians Organized Against Lupus (GOAL) Cohort: Advancing Health DisparitiesU01DP005119 · DP · EMORY UNIVERSITY · PI DRENKARD, CRISTINA MARTA, LIM, SUNG SAM · 2014 to 2018
$4.8M
A Model System for the Study of Human B-cell ToleranceR37AI049660 · NIAID · UNIVERSITY OF ROCHESTER · PI SANZ, IGNACIO E. · 2010 to 2019
$3.7M
NCCDPHP CDC HHS U01 DP005119NCCDPHP CDC HHS U01 DP006488NCCDPHP CDC HHS U01 DP006698NIAID NIH HHS R37 AI049660NIAID NIH HHS U19 AI110483
6 · The paper itself

Abstract

objectiveWhile the contribution of B-cells to SLE is well established, its role in chronic cutaneous lupus erythematosus (CCLE) remains unclear. Here, we compare B-cell and serum auto-antibody profiles between patients with systemic lupus erythematosus (SLE), CCLE, and overlap conditions.

methodsB-cells were compared by flow cytometry amongst healthy controls, CCLE without systemic lupus (CCLE+/SLE-) and SLE patients with (SLE+/CCLE+) or without CCLE (SLE+/CCLE-). Serum was analyed for autoreactive 9G4+, anti-double-stranded DNA, anti-chromatin and anti-RNA antibodies by ELISA and for anti-RNA binding proteins (RBP) by luciferase immunoprecipitation.

resultsPatients with CCLE+/SLE- share B-cell abnormalities with SLE including decreased unswitched memory and increased effector B-cells albeit at a lower level than SLE patients. Similarly, both SLE and CCLE+/SLE- patients have elevated 9G4+ IgG autoantibodies despite lower levels of anti-nucleic acid and anti-RBP antibodies in CCLE+/SLE-. CCLE+/SLE- patients could be stratified into those with SLE-like B-cell profiles and a separate group with normal B-cell profiles. The former group was more serologically active and more likely to have disseminated skin lesions.

conclusionCCLE displays perturbations in B-cell homeostasis and partial B-cell tolerance breakdown. Our study demonstrates that this entity is immunologically heterogeneous and includes a disease segment whose B-cell compartment resembles SLE and is clinically associated with enhanced serological activity and more extensive skin disease. This picture suggests that SLE-like B-cell changes in primary CCLE may help identify patients at risk for subsequent development of SLE. B-cell profiling in CCLE might also indentify candidates who would benefit from B-cell targeted therapies.

Indexed as

AdultAntibodies, AntinuclearAutoantibodiesB-LymphocytesB-Lymphocyte SubsetsChromatinChronic DiseaseDNAFemaleFlow CytometryHumansImmunologic MemoryImmunophenotypingLupus Erythematosus, CutaneousLupus Erythematosus, SystemicMaleAntibodies, AntinuclearAutoantibodiesChromatinDNARNARNA-Binding ProteinsautoantibodiesautoimmunityB-lymphocyteslupus erythematosussystemic

Identifiers

PMID34083207
PMCPMC8906255
OpenAlexW3164537790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.